Jeannie Woith Discusses the Benefits of Low-Level Laser Therapy for Oral Mucositis

The FDA approved a perioperative pembrolizumab regimen in head and neck squamous cell carcinoma, marking the first approval in this cancer type in 6 years.

Shawna Douglas, BSN, RN, discusses the role that nurse navigators play in caring for patients with head and neck cancer.

Belzutifan has become the first FDA-approved oral therapy for pheochromocytoma or paraganglioma.

New data show strong overall survival rates, building on previously reported outcomes with efti plus pembrolizumab for head and neck squamous cell carcinoma.

Approvals in oncology during April included treatments for breast cancer, colorectal cancer, and more.

Oncology nurses can encourage clinical trial enrollment for patients with anaplastic thyroid cancer, a rare and aggressive cancer type.